ArticleFrontiers in oncology2025
Malignant adenomyoepithelioma of the breast with axillary lymph node metastasis: a case report and review of the literature.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Malignant adenomyoepithelioma of the breast with contralateral homologous tumor and ductal carcinomaInternational journal of surgery case reports · 2026Article
- Malignant breast adenomyoepithelioma with diagnostic discordance: a case report and literature review.Frontiers in oncology · 2026Article
- Malignant adenomyoepithelioma of the breast: a rare case report and literature review.Journal of surgical case reports · 2026Article
- Malignant adenomyoepithelioma of the breast with axillary metastasis: a case report in a patient undergoingFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adenomyoepithelioma (AME) is a relatively rare type of tumor formed by the coordinated proliferation of glandular epithelial cells and myoepithelial cells. Clinically, most of them are benign, while malignant ones are extremely rare. Malignant breast adenomyoepithelioma is somewhat invasive and may recur locally or metastasize distantly through the vascular pathway. However, reports on axillary lymph node metastasis are scarce. In this case, we present an extremely rare instance of malignant breast adenomyoepithelioma with axillary lymph node metastasis. By combining previous studies, we conduct an in-depth analysis of the clinicopathological features, treatment methods, and prognosis of this disease, and propose targeted diagnostic and treatment suggestions. Case presentation: A 64-year-old woman initially presented with no abnormalities in the axillary lymph nodes upon clinical examination or imaging. Following the diagnosis of malignant adenomyoepithelioma, the patient underwent unilateral mastectomy. Six months after surgery, the patient developed ipsilateral axillary lymph node enlargement, which was confirmed by pathological examination as metastasis of malignant adenomyoepithelioma of the breast to the axillary lymph nodes. The patient underwent axillary lymph node dissection, followed by four cycles of epirubicin and cyclophosphamide (AC) chemotherapy. Nine months after the operation, the patient returned to our outpatient clinic for follow-up, and the examination results showed no signs of recurrence or distant metastasis. Conclusion: We meticulously described the clinical symptoms, signs, and imaging characteristics of both the primary lesion of malignant adenomyoepithelioma of the breast and its axillary metastasis in the patient. Through a comparison of the pathologic features between the primary breast lesion and the axillary metastatic lymph nodes, we found a certain degree of consistency in terms of microscopic pathologic features and immunohistochemical molecular expression. Furthermore, we conducted an extensive review of the literature on breast malignant adenomyoepithelioma over the past decade. By summarizing the clinicopathological characteristics, treatment modalities, and prognosis of the patients, we found that patients with breast malignant adenomyoepithelioma have a certain risk of recurrence and metastasis. Notably, even when the clinical examination of axillary lymph nodes yields negative results and imaging shows no enlargement, a more assertive surgical approach may still be necessary. Specifically, a sentinel lymph node biopsy, despite the potential for false-negative outcomes, could be advantageous for the patient's prognosis by enabling early determination of the need for axillary lymph node dissection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.